Estimating the fitness cost and benefit of cefixime resistance in to inform prescription policy: A modelling study

1. Public Health England. Infection Report: HIV—STIs. Public Health England; 2015. https://www.gov.uk/government/publications/health-protection-report-volume-8-2014

2. Lewis DA. The Gonococcus fights back: is this time a knock out? Sexually Transmitted Infections. 2010;86(6):415–421. doi: 10.1136/sti.2010.042648 20656721

3. Grad YH, Kirkcaldy RD, Trees D, Dordel J, Harris SR, Goldstein E, et al. Genomic epidemiology of Neisseria gonorrhoeae with reduced susceptibility to cefixime in the USA: A retrospective observational study. The Lancet Infectious Diseases. 2014;14(3):220–226. doi: 10.1016/S1473-3099(13)70693-5 24462211

4. Bignell C, FitzGerald M. UK national guideline for the management of gonorrhoea in adults, 2011. International Journal of STD & AIDS. 2011;22(10):541–547. doi: 10.1258/ijsa.2011.011267 21998172

5. Bignell C, Unemo M. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. International Journal of STD & AIDS. 2013;24(2):85–92. doi: 10.1177/0956462412472837 24400344

6. Centers for Disease Control and Prevention. Gonococcal Infections—2015 STD Treatment Guidelines; 2015.

7. Chisholm SA, Wilson J, Alexander S, Tripodo F, Al-Shahib A, Schaefer U, et al. An outbreak of high-level azithromycin resistant Neisseria gonorrhoeae in England. Sexually Transmitted Infections. 2015; doi: 10.1136/sextrans-2015-052312 26601852

8. Ison CA, Town K, Obi C, Chisholm S, Hughes G, Livermore DM, et al. Decreased susceptibility to cephalosporins among gonococci: Data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007–2011. The Lancet Infectious Diseases. 2013;13(9):762–768. doi: 10.1016/S1473-3099(13)70143-9 23764300

9. GRASP Steering Group. Annual Report 2000. London: Health Protection Agency; 2001.

10. GRASP Steering Group. The Gonococcal Resistance to Antimicrobials Surveillance Programme 2001. London: Health Protection Agency; 2002.

11. GRASP Steering Group. The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) 2002. London: Health Protection Agency; 2003.

12. GRASP Steering Group. Annual Report Year 2003. London: Health Protection Agency; 2004.

13. GRASP Steering Group. The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) Year 2004 report. London: Health Protection Agency; 2005.

14. GRASP Steering Group. The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) 2005 report. London: Health Protection Agency; 2006.

15. GRASP Steering Group. Annual Report 2006. London: Health Protection Agency; 2007.

16. GRASP Steering Group. Annual Report 2007. London: Health Protection Agency; 2008.

17. GRASP Steering Group. The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) Year 2008 report. London: Health Protection Agency; 2009.

18. GRASP Steering Group. Health Protection Report: Gonococcal Resistance to Antimicrobials Surveillance Programme in England and Wales (GRASP) report of 2009 data. London: Health Protection Agency; 2010. 34.

19. GRASP Steering Group. GRASP 2010 Report. London: Health Protection Agency; 2011.

20. GRASP Steering Group. GRASP 2011 Report: The Gonococcal Resistance to Antimicrobials Surveillance Programme. London: Health Protection Agency; 2012.

21. GRASP Steering Group. GRASP 2012 Report: The Gonococcal Resistance to Antimicrobials Surveillance Programme. London: Public Health England; 2013.

22. GRASP Steering Group. GRASP 2013 Report: The Gonococcal Resistance to Antimicrobials Surveillance Programme (England and Wales); 2014.

23. GRASP Steering Group. The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) 2014 report. London: Public Health England; 2015.

24. GRASP Steering Group. Surveillance of antimicrobial resistance in Neisseria gonorrhoeae Key findings from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP); 2016. October.

25. Allen VG, Mitterni L, Seah C, Rebbapragada A, Martin IE, Lee C, et al. Neisseria gonorrhoeae Treatment Failure and Susceptibility to Cefixime in Toronto, Canada. JAMA. 2013;309(2):163. doi: 10.1001/jama.2012.176575 23299608

26. Bignell C. National Guideline on the Diagnosis and Treatment of Gonorrhoea in Adults 2005; 2005. https://www.bashh.org/documents/116/116.pdf

27. World Health Organization. Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. World Health Organization; 2012.

28. Ison C, Hussey J, Sankar K, Evans J, Alexander S. Gonorrhoea treatment failures to cefixime and azithromycin in England, 2010. Eurosurveillance. 2011;16(14):1–4.

29. Forsyth S, Penney P, Rooney G. Cefixime-resistant Neisseria gonorrhoeae in the UK: a time to reflect on practice and recommendations. International Journal of STD and AIDS. 2011;22(5):296–297. doi: 10.1258/ijsa.2009.009191 21571983

30. Grad YH, Goldstein E, Lipsitch M, White PJ. Improving Control of Antibiotic-Resistant Gonorrhea by Integrating Research Agendas Across Disciplines: Key Questions Arising From Mathematical Modeling. Journal of Infectious Diseases. 2016;213(6):883–890. doi: 10.1093/infdis/jiv517 26518045

31. Bissessor M, Tabrizi SN, Fairley CK, Danielewski J, Whitton B, Bird S, et al. Differing Neisseria gonorrhoeae bacterial loads in the pharynx and rectum in men who have sex with men: Implications for gonococcal detection, transmission, and control. Journal of Clinical Microbiology. 2011;49(12):4304–4306. doi: 10.1128/JCM.05341-11 21956992

32. Kent CK, Chaw JK, Wonq W, Liska S, Gibson S, Hubbard G, et al. Prevalence of rectal, urethral, and pharyngeal chlamydia and gonorrhea detected in 2 clinical settings among men who have sex with men: San Francisco, California, 2003. Clinical Infectious Diseases. 2005;41(1):67–74. doi: 10.1086/430704 15937765

33. Norris Turner A, Carr Reese P, Ervin M, Davis JA, Fields KS, Bazan JA. HIV, rectal chlamydia and rectal gonorrhea in men who have sex with men attending an STD clinic in a midwestern US city. Sexually Transmitted Diseases. 2013;40(6). doi: 10.1097/OLQ.0b013e31828fd163.HIV

34. Didelot X, Dordel J, Whittles L, Collins C, Bilek N, Bishop C, et al. Genomic analysis and comparison of two gonorrhoea outbreaks. mBio. 2016; e00525–16. doi: 10.1128/mBio.00525-16 27353752

35. Savage EJ, Mohammed H, Leong G, Duffell S, Hughes G. Improving surveillance of sexually transmitted infections using mandatory electronic clinical reporting: the genitourinary medicine clinic activity dataset, England, 2009 to 2013. Eurosurveillance. 2014;19(48):20981. doi: 10.2807/1560-7917.ES2014.19.48.20981

36. Marcus U, Hickson F, Weatherburn P, Schmidt AJ. Estimating the size of the MSM populations for 38 European countries by calculating the survey-surveillance discrepancies (SSD) between self-reported new HIV diagnoses from the European MSM internet survey (EMIS) and surveillance-reported HIV diagnoses am. BMC Public Health. 2013;13(1):919. doi: 10.1186/1471-2458-13-919 24088198

37. Mercer CH, Tanton C, Prah P, Erens B, Sonnenberg P, Clifton S, et al. Changes in sexual attitudes and lifestyles in Britain through the life course and over time: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). The Lancet. 2013;382(9907):1781–1794. doi: 10.1016/S0140-6736(13)62035-8 24286784

38. Office for National Statistics. United Kingdom population mid-year estimate; 2016. http://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationestimates/timeseries/ukpop/pop

39. Hosenfeld CB, Workowski Ka, Berman S, Zaidi A, Dyson J, Mosure D, et al. Repeat infection with Chlamydia and gonorrhea among females: a systematic review of the literature. Sexually Transmitted Diseases. 2009;36(8):478–489. doi: 10.1097/OLQ.0b013e3181a2a933 19617871

40. Schmidt K, Schneider H, Lindstrom J, Boslego J, Warren R, Van de Verg L, et al. Homologous Gonococci in Male Volunteers. Sexually Transmitted Diseases. 2001; 28(10):555–564.

41. Platt R, Rice P, McCormack W. Risk of acquiring gonorrhea and prevalence of abnormal adnexal findings among women recently exposed to gonorrhea. Journal of Acquired Immune Deficiency Syndromes. 1983;250:3205–3209. doi: 10.1001/jama.250.23.3205

42. Johnson LF, Dorrington RE, Bradshaw D. The role of immunity in the epidemiology of gonorrhoea, chlamydial infection and trichomoniasis: insights from a mathematical model. Epidemiology and Infection. 2011;139(12):1875–1883. doi: 10.1017/S0950268811000045 21299913

43. Handsfield HH, Lipman TO, Harnisch JP, Tronca E, Holmes KK. Asymptomatic Gonorrhea in Men. New England Journal of Medicine. 1974;290(3):117–123. doi: 10.1056/NEJM197401172900301 4202519

44. Diekmann O, Heesterbeek JAP, Metz JAJ. On the definition and the computation of the basic reproduction ratio R0 in models for infectious diseases in heterogeneous populations. Journal of Mathematical Biology. 1990;28(4):365–382. doi: 10.1007/BF00178324 2117040

45. Wetten S, Mohammed H, Yung M, Mercer CH, Cassell JA, Hughes G. Diagnosis and treatment of chlamydia and gonorrhoea in general practice in England 2000–2011: a population-based study using data from the UK Clinical Practice Research Datalink. BMJ Open. 2015; 5:e007776. doi: 10.1136/bmjopen-2015-007776 26022269

46. Del Moral P, Doucet A, Jasra A. Sequential Monte Carlo samplers. Journal of the Royal Statistical Society Series B: Statistical Methodology. 2006;68(3):411–436. doi: 10.1111/j.1467-9868.2006.00553.x

47. Andrieu C, Doucet A, Holenstein R. Particle Markov chain Monte Carlo methods. Journal of the Royal Statistical Society Series B-Statistical Methodology. 2010;72(3):269–342. doi: 10.1111/j.1467-9868.2009.00736.x

48. King AA, Nguyen D, Ionides EL. Statistical Inference for Partially Observed Markov Processes via the R Package pomp. Journal of Statistical Software. 2016;69(12):1–43. doi: 10.18637/jss.v069.i12

49. Plummer M, Best N, Cowles K, Vines K. CODA: convergence diagnosis and output analysis for MCMC. R News. 2006;6(March):7–11. doi: 10.1159/000323281

50. Gelman A, Rubin DB. Inference from Iterative Simulation Using Multiple Sequences. Statistical Science. 1992;7(4):457–472.

51. Brooks SP, Gelman AG. General methods for monitoring convergence of iterative simulations. Journal of Computational and Graphical Statistics. 1998;7(4):434–455. doi: 10.2307/1390675

52. Yorke J, Hethcote H, Nold A. Dynamics and control of the transmission of gonorrhea. Sexually Transmitted Diseases. 1978;5(2):51–56. doi: 10.1097/00007435-197804000-00003 10328031

53. Garnett GP, Mertz KJ, Finelli L, Levine WC, St Louis ME. The transmission dynamics of gonorrhoea: modelling the reported behaviour of infected patients from Newark, New Jersey. Philosophical transactions of the Royal Society of London Series B, Biological sciences. 1999;354(1384):787–97. doi: 10.1098/rstb.1999.0431 10365404

54. White PJ, Ward H, Cassell JA, Mercer CH, Garnett GP. Vicious and virtuous circles in the dynamics of infectious disease and the provision of health care: gonorrhea in Britain as an example. The Journal of infectious diseases. 2005;192(5):824–836. doi: 10.1086/432004 16088832

55. Fairley CK, Chen MY, Bradshaw CS, Tabrizi SN. Is it time to move to nucleic acid amplification tests screening for pharyngeal and rectal gonorrhoea in men who have sex with men to improve gonorrhoea control? Sexual Health. 2011;8(1):9–11. doi: 10.1071/SH10134 21371376

56. Jin F, Prestage GP, Mao L, Kippax SC, Pell CM, Donovan B, et al. Incidence and risk factors for urethral and anal gonorrhoea and chlamydia in a cohort of HIV-negative homosexual men: the Health in Men Study. Sexually Transmitted Infections. 2007;83(2):113–119. doi: 10.1136/sti.2006.021915 17005541

57. Harrison WO, Hooper RR, Wiesner PJ, Campbell AF, Karney WW, Reynolds GH, et al. A trial of minocycline given after exposure to prevent gonorrhea. New England Journal of Medicine. 1979;300(19):1074–1078. doi: 10.1056/NEJM197905103001903 107450

58. McCutchan JA. Epidemiology of venereal urethritis: comparison of gonorrhea and nongonococcal urethritis. Reviews of Infectious Diseases. 1984;6(5):669–688. 6438766

59. Korenromp EL, Sudaryo MK, de Vlas SJ, Gray RH, Sewankambo NK, Serwadda D, et al. What proportion of episodes of gonorrhoea and chlamydia becomes symptomatic? International journal of STD & AIDS. 2002;13(2):91–101. doi: 10.1258/0956462021924712 11839163

60. Public Health England. STI diagnoses & rates in England by gender, 2006–2015; 2015.

61. Gelman A, Meng XL, Stern H. Posterior predictive assessment of model fitness via realized discrepancies. Vol.6, No.4. Statistica Sinica. 1996;6(4):733–807.

62. Dietz K. The estimation of the basic reproduction number for infectious diseases. Statistical Methods in Medical Research. 1993;2(1):23–41. doi: 10.1177/096228029300200103 8261248

63. Garnett G, Anderson R. Contact Tracing and the Estimation of Sexual Mixing Patterns. Sexually Transmitted Diseases. 1993;20(4):181–191. doi: 10.1097/00007435-199307000-00001 8211533

64. Ghani A, Swinton J, Garnett G. The Role of Sexual Partnership Networks in the Epidemology of Gonorrhea. Sexually Transmitted Diseases. 1997;24(1):45–56. doi: 10.1097/00007435-199701000-00009 9018783

65. Fingerhuth SM, Bonhoeffer S, Low N, Althaus CL. Antibiotic-Resistant Neisseria gonorrhoeae Spread Faster with More Treatment, Not More Sexual Partners. PLoS Pathogens. 2016;12(5):e1005611. doi: 10.1371/journal.ppat.1005611 27196299

66. Bignell C. 2009 European (IUSTI / WHO) Guideline on the Diagnosis and Treatment of Gonorrhoea in Adults. International Journal of STD & AIDS. 2009;20:453–457. doi: 10.1258/ijsa.2009.009160 19541885

67. Bignell C, Garley J. Azithromycin in the treatment of infection with Neisseria gonorrhoeae. Sexually Transmitted Infections. 2010;86:422–426. doi: 10.1136/sti.2010.044586 20940153

68. Lipsitch M, Bergstrom CT, Levin BR. The epidemiology of antibiotic resistance in hospitals: paradoxes and prescriptions. Proceedings of the National Academy of Sciences of the United States of America. 2000;97(4):1938–1943. doi: 10.1073/pnas.97.4.1938 10677558

69. Kouyos RD, zur Wiesch PA, Bonhoeffer S. On being the right size: The impact of population size and stochastic effects on the evolution of drug resistance in hospitals and the community. PLoS Pathogens. 2011;7(4): e1001334. doi: 10.1371/journal.ppat.1001334 21533212

70. Melnyk AH, Wong A, Kassen R. The fitness costs of antibiotic resistance mutations. Evolutionary Applications. 2015;8(3):273–283. doi: 10.1111/eva.12196 25861385

71. Didelot X, Walker AS, Peto TE, Crook DW, Wilson DJ. Within-host evolution of bacterial pathogens. Nature Reviews Microbiology. 2016;14(3):150–162. doi: 10.1038/nrmicro.2015.13 26806595

72. Fifer H, Natarajan U, Jones L, Alexander S, Hughes G, Golparian D, et al. Failure of Dual Antimicrobial Therapy in Treatment of Gonorrhea. New England Journal of Medicine. 2016;374(25):2504–2506. doi: 10.1056/NEJMc1512757 27332921

73. Town K, Obi C, Quaye N, Chisholm S, Hughes G. Drifting towards ceftriaxone treatment failure in gonorrhoea: risk factor analysis of data from the Gonococcal Resistance to Antimicrobials Surveillance Programme in England and Wales. Sexually Transmitted Infections. 2017;93(1):39–45. doi: 10.1136/sextrans-2016-052583 27382010

74. Pond MJ, Hall CL, Miari VF, Cole M, Laing KG, Jagatia H, et al. Accurate detection of Neisseria gonorrhoeae ciprofloxacin susceptibility directly from genital and extragenital clinical samples: Towards genotype-guided antimicrobial therapy. Journal of Antimicrobial Chemotherapy. 2016;71(4):897–902. doi: 10.1093/jac/dkv432 26817487

75. Buckley C, Trembizki E, Donovan B, Chen M, Freeman K, Guy R, et al. Real-time PCR detection of Neisseria gonorrhoeae susceptibility to penicillin. Journal of Antimicrobial Chemotherapy. 2016;71:3090–3095. doi: 10.1093/jac/dkw291 27494921

76. Grad YH, Harris SR, Kirkcaldy RD, Green AG, Marks DS, Bentley SD, et al. Genomic epidemiology of gonococcal resistance to extended-spectrum cephalosporins, macrolides, and fluoroquinolones in the United States, 2000–2013. Journal of Infectious Diseases. 2016;214(10):1579–87. doi: 10.1093/infdis/jiw420 27638945

77. Eyre DW, De Silva D, Cole K, Peters J, Cole MJ, Grad YH, et al. WGS to predict antibiotic MICs for Neisseria gonorrhoeae. Journal of Antimicrobial Chemotherapy. 2017; doi: 10.1093/jac/dkx067 28333355

78. Kirkcaldy RD, Hook EW, Olusegun O, del Rio C, Kubin G, Zenilman JM, et al. Trends in Neisseria gonorrhoeae susceptibility to cephalosporins in the United States, 2006–2014. JAMA. 2015;314(17):1869–1871. doi: 10.1001/jama.2015.10347 26529166

79. Kirkcaldy RD, Schlanger K, Papp JR, Torrone EA. Considerations for Strengthening Surveillance of Neisseria gonorrhoeae Antimicrobial Resistance and Interpreting Surveillance Data. Sexually Transmitted DIseases. 2017;44(3):154–156. doi: 10.1097/OLQ.0000000000000584 28178113